Molecular modeling approaches of selective adenosine receptor type 2A agonists as potential anti-inflammatory drugs
- 6 May 2020
- journal article
- research article
- Published by Informa UK Limited in Journal of Biomolecular Structure and Dynamics
- Vol. 39 (9), 1-13
- https://doi.org/10.1080/07391102.2020.1761878
Abstract
Adenosine A2A receptor (A2AR) is the predominant receptor in immune cells, where its activation triggers cAMP-mediated immunosuppressive signaling and the underlying inhibition of T cells activation and T cells-induced effects mediated by cAMP-dependent kinase proteins mechanisms. In this study, were used ADME/Tox, molecular docking and molecular dynamics simulations to investigate selective adenosine A2AR agonists as potential anti-inflammatory drugs. As a result, we obtained two promising compounds (A and B) that have satisfactory pharmacokinetic and toxicological properties and were able to interact with important residues of the A2AR binding cavity and during the molecular dynamics simulations were able to keep the enzyme complexed.Keywords
This publication has 55 references indexed in Scilit:
- In Vitro Blood–Brain Barrier Models: Current and Perspective TechnologiesJournal of Pharmaceutical Sciences, 2012
- Synthesis and Pharmacological Evaluation of Dual Acting Antioxidant A2A Adenosine Receptor AgonistsJournal of Medicinal Chemistry, 2012
- Ammonium Phosphorodithioate: A Mild, Easily Handled, Efficient, and Air-Stable Reagent for the Conversion of Amides into ThioamidesSynlett, 2011
- Structure of an Agonist-Bound Human A 2A Adenosine ReceptorScience, 2011
- 5-FU Metabolism in Cancer and Orally-Administrable 5-FU DrugsCancers, 2010
- Ligand Binding and Subtype Selectivity of the Human A2A Adenosine ReceptorPublished by Elsevier BV ,2010
- SAR of a series of inhaled A2A agonists and comparison of inhaled pharmacokinetics in a preclinical model with clinical pharmacokinetic dataBioorganic & Medicinal Chemistry Letters, 2009
- CHARMM general force field: A force field for drug‐like molecules compatible with the CHARMM all‐atom additive biological force fieldsJournal of Computational Chemistry, 2009
- Improved protein–ligand docking using GOLDProteins-Structure Function and Bioinformatics, 2003
- A Synthesis of the Potent A2Selective Adenosine Agonist N6-[2-(3,5-Dimethoxyphenyl)-2-(2-Methylphenyl)Ethyl]Adenosine, and Its 5′-N-Ethyl Ribofuranuronamide DerivativeNucleosides and Nucleotides, 1989